QuidelOrtho Corp (QDEL)
36.18
-2.78
(-7.14%)
USD |
NASDAQ |
Nov 15, 16:00
36.20
+0.02
(+0.06%)
After-Hours: 20:00
QuidelOrtho Research and Development Expense (TTM): 232.50M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 232.50M |
| June 30, 2024 | 238.10M |
| March 31, 2024 | 244.20M |
| December 31, 2023 | 247.30M |
| September 30, 2023 | 250.50M |
| June 30, 2023 | 254.60M |
| March 31, 2023 | 226.40M |
| December 31, 2022 | 190.50M |
| September 30, 2022 | 152.30M |
| June 30, 2022 | 110.40M |
| March 31, 2022 | 98.80M |
| December 31, 2021 | 95.70M |
| September 30, 2021 | 95.10M |
| June 30, 2021 | 92.85M |
| March 31, 2021 | 91.22M |
| December 31, 2020 | 84.29M |
| September 30, 2020 | 73.72M |
| June 30, 2020 | 64.25M |
| March 31, 2020 | 55.00M |
| December 31, 2019 | 52.55M |
| September 30, 2019 | 50.27M |
| June 30, 2019 | 51.40M |
| March 31, 2019 | 52.96M |
| December 31, 2018 | 51.65M |
| September 30, 2018 | 49.68M |
| Date | Value |
|---|---|
| June 30, 2018 | 44.05M |
| March 31, 2018 | 38.39M |
| December 31, 2017 | 33.64M |
| September 30, 2017 | 30.48M |
| June 30, 2017 | 31.81M |
| March 31, 2017 | 33.84M |
| December 31, 2016 | 38.67M |
| September 30, 2016 | 41.10M |
| June 30, 2016 | 40.72M |
| March 31, 2016 | 40.17M |
| December 31, 2015 | 35.51M |
| September 30, 2015 | 34.77M |
| June 30, 2015 | 37.86M |
| March 31, 2015 | 36.88M |
| December 31, 2014 | 37.91M |
| September 30, 2014 | 40.00M |
| June 30, 2014 | 35.96M |
| March 31, 2014 | 35.78M |
| December 31, 2013 | 34.22M |
| September 30, 2013 | 30.21M |
| June 30, 2013 | 27.84M |
| March 31, 2013 | 26.74M |
| December 31, 2012 | 27.72M |
| September 30, 2012 | 27.20M |
| June 30, 2012 | 28.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
52.55M
Minimum
Dec 2019
254.60M
Maximum
Jun 2023
147.51M
Average
104.60M
Median
Research and Development Expense (TTM) Benchmarks
| Abbott Laboratories | 2.795B |
| Becton Dickinson & Co | 1.19B |
| Repligen Corp | 41.81M |
| Perspective Therapeutics Inc | 28.53M |
| Xtant Medical Holdings Inc | 2.145M |